Compare Cytokinetics Inc (CYTK) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs McCormick & Company, Incorporated — how do they compare? Cytokinetics Inc trades at $73.37 (market cap $10.21B), while McCormick & Company, Incorporated trades at $54.51 (market cap $14.63B). The key difference: McCormick & Company, Incorporated is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.53% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MKC | |
|---|---|---|
Market Cap | $10.21B | $14.63B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $72.26 |
52-Week Low | $35.33 | $45.60 |
Enterprise Value | $10.32B | $19.23B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 1.06% with a bearish technical signal. The company shows strong commercial momentum with Myqorzo gaining traction internationally, but faces significant financial challenges including negative gross margin of -372.55% and net income margin of -1,321.12%. Recent Q2 2026 earnings beat revenue estimates despite posting losses, while regulatory approvals in the UK expand market access.
Investment outlook balances promising drug pipeline against substantial financial losses. Analyst consensus remains overwhelmingly bullish with 97% buy ratings and $111.14 price target, representing 47% upside potential. Key risks include high cash burn, competitive pressures, and the need for continued financing to support operations and drug development.
MKC trades at $54.45, up 2.95% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a net income margin of 21.91% and ROE of 25.7%, supported by recent earnings beats. Valuation metrics like a P/E of 8.81 suggest potential undervaluation. Key developments include the planned merger with Unilever's food business, expected to close in 2027, which could significantly expand the company's scale and market presence.
The outlook for MKC is positive, driven by merger synergies, consistent dividend growth, and margin expansion. Risks include integration challenges with Unilever, soft consumer volumes, and economic sensitivity. Analysts project a 9.6% upside to the $59.67 consensus target, with a majority hold rating reflecting cautious optimism amid transformative changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
